Stockscreener 앱 받기
24.50
6.22%
1.435
전일 마감가:
$23.07
열려 있는:
$23.47
하루 거래량:
560.59K
Relative Volume:
0.20
시가총액:
$3.12B
수익:
$24.05M
순이익/손실:
$-243.33M
주가수익비율:
-8.1672
EPS:
-3.0004
순현금흐름:
$-370.18M
1주 성능:
-3.60%
1개월 성능:
-16.62%
6개월 성능:
+514.16%
1년 성능:
+512.62%
1일 변동 폭
$23.44
$24.94
1주일 범위
$22.08
$25.71
52주 변동 폭
$2.7601
$30.60
Alumis Inc Stock (ALMS) Company Profile
명칭
Alumis Inc
전화
650-231-6625
주소
280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALMS vs VRTX, REGN, ALNY, ARGX, INSM
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALMS
Alumis Inc
|
24.51 | 2.93B | 24.05M | -243.33M | -370.18M | -3.0004 |
VRTX
Vertex Pharmaceuticals Inc
|
457.52 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.06 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
324.95 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
692.38 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.04 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Alumis Inc Stock (ALMS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-11 | 개시 | Raymond James | Strong Buy |
| 2026-02-25 | 개시 | Stifel | Buy |
| 2026-01-21 | 개시 | Chardan Capital Markets | Buy |
| 2025-07-25 | 개시 | Wells Fargo | Overweight |
| 2025-06-10 | 재개 | Guggenheim | Buy |
| 2025-01-30 | 개시 | Oppenheimer | Outperform |
| 2024-10-31 | 개시 | Robert W. Baird | Outperform |
| 2024-10-17 | 개시 | H.C. Wainwright | Buy |
| 2024-07-23 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-07-23 | 개시 | Guggenheim | Buy |
| 2024-07-23 | 개시 | Leerink Partners | Outperform |
| 2024-07-23 | 개시 | Morgan Stanley | Overweight |
모두보기
Alumis Inc 주식(ALMS)의 최신 뉴스
Alumis (NASDAQ:ALMS) Shares Down 5.8%Here's What Happened - MarketBeat
Why Alumis Inc. Stock Is Suddenly Sinking - TipRanks
Aug PostEarnings: Can Alumis Inc ride the EV wave2026 Highlights & Reliable Volume Spike Alerts - baoquankhu1.vn
Chardan Capital initiates coverage of Alumis (ALMS) with buy recommendation - MSN
Alumis Inc. (ALMS) Receives a Buy from Morgan Stanley - The Globe and Mail
Short Covering: Is Alumis Inc gaining market shareJobs Report & Technical Analysis for Trade Confirmation - baoquankhu1.vn
Alumis (ALMS) Q4 Loss Of US$92.9 Million Tests Bullish Growth Narrative - simplywall.st
Alumis (ALMS) Sees Price Target Raised by Morgan Stanley | ALMS Stock News - GuruFocus
Alumis (NASDAQ:ALMS) Price Target Raised to $38.00 - MarketBeat
Alumis (NASDAQ:ALMS) Given New $38.00 Price Target at Chardan Capital - MarketBeat
Alumis Reports Positive Phase 3 Results for Envudeucitinib in Psoriasis, Financial Highlights, and 2026 Milestones - Minichart
ALMS Stock Chart | ALUMIS INC (NASDAQ:ALMS) - ChartMill
Alumis (NASDAQ:ALMS) Issues Quarterly Earnings Results - MarketBeat
[S-3ASR] ALUMIS INC. SEC Filing - Stock Titan
Alumis : Corporate PresentationMarch 2026 - marketscreener.com
Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements - The Manila Times
Alumis 2025 10-K: $24.05M revenue, $(2.86) EPS (loss) - TradingView
Alumis (NASDAQ: ALMS) advances TYK2 pipeline and closes $238M ACELYRIN stock merger - Stock Titan
Alumis (ALMS) details 2025 results, envudeucitinib NDA plan and cash raise - Stock Titan
A psoriasis pill hit late-stage goals; Alumis plans U.S. filing in 2026 - Stock Titan
ALMS Earnings History & Surprises | EPS & Revenue Results | ALUMIS INC (NASDAQ:ALMS) - ChartMill
Alumis presents phase 3 psoriasis trial data at dermatology meeting By Investing.com - Investing.com India
**Key Clinical Data to Be Revealed Soon** Biopharmaceutical company Alumis Inc. announced that the phase III clinical trial data of its lead candidate drug Envudeucitinib for the treatment of moderate-to-severe plaque psoriasis has been selected for the "Lat - Bitget
**Key Clinical Data to Be Revealed Soon** Biopharmaceutical company Alumis Inc. announced that the phase III clinical trial data of its lead candidate drug Envudeucitinib for the treatment of moderate to severe plaque psoriasis has been selected for the "Lat - Bitget
Alumis presents phase 3 psoriasis trial data at dermatology meeting - Investing.com
Alumis Announces Late-Breaker Oral Presentation of Phase 3 Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis at 2026 American Academy of Dermatology Annual Meeting - The Manila Times
Experimental oral psoriasis drug’s Phase 3 results to debut at skin conference - Stock Titan
Huge insider buying now at this insurance giant and 2 biotechs - MSN
Alumis (NASDAQ:ALMS) Trading Down 3.5%Here's What Happened - MarketBeat
ALMS Technical Analysis & Stock Price Forecast - Intellectia AI
Wells Fargo Initiates Coverage of Alumis (ALMS) with Overweight Recommendation - MSN
Alumis Inc. (NASDAQ:ALMS) Sees Significant Drop in Short Interest - MarketBeat
Alumis Inc. (ALMS) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Alumis Inc expected to post a loss of 98 cents a shareEarnings Preview - TradingView
Inflation Data: Can Alumis Inc ride the EV waveGold Moves & Low Risk Investment Opportunities - baoquankhu1.vn
Raymond James initiates coverage of Alumis (ALMS) with strong buy recommendation - MSN
Raymond James Starts ALMS (Alumis Inc. Common Stock) at Strong Buy Mar 2026 - Meyka
Alumis (NASDAQ:ALMS) Stock Price Down 6.7%Should You Sell? - MarketBeat
This Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday - Benzinga
Assessing Alumis (ALMS) Valuation After A Strong Multi‑Month Share Price Run - Yahoo Finance
Raymond James initiates Alumis stock coverage citing psoriasis drug potential - Investing.com Nigeria
Raymond James initiates Alumis stock coverage citing psoriasis drug potential By Investing.com - Investing.com South Africa
Alumis Teases TYK2 Catalysts at Leerink: Phase III Psoriasis Wins, NDA Plan and Lupus Readout Ahead - Yahoo Finance
TYK2 Validation and Expanding Indications Drive Buy Rating and $40 Price Target for Alumis - TipRanks
Certain Options of Alumis Inc. are subject to a Lock-Up Agreement Ending on 9-MAR-2026. - marketscreener.com
Phase III wins lift Alumis, Corcept shares in January - bioworld.com
Alumis to Present at the Leerink Partners Global Healthcare Conference - The Manila Times
ALMS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Biopharma CEO to appear in live Leerink healthcare fireside chat - Stock Titan
Alumis Inc. (NASDAQ:ALMS) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Alumis Shares Phase 3 Psoriasis Details, Targets 2H NDA Filing at Oppenheimer Healthcare Conference - Yahoo Finance
Alumis Inc (ALMS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Alumis Inc 주식 (ALMS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Foresite Labs, LLC | 10% Owner |
Jan 08 '26 |
Buy |
17.00 |
411,764 |
6,999,988 |
5,702,536 |
| Foresite Capital Management VI | 10% Owner |
Jan 08 '26 |
Buy |
17.00 |
411,764 |
6,999,988 |
5,702,536 |
| Tananbaum James B. | Director |
Jan 08 '26 |
Buy |
17.00 |
411,764 |
6,999,988 |
5,702,536 |
| AKKARAJU SRINIVAS | Director |
Dec 05 '25 |
Buy |
9.84 |
186,377 |
1,833,760 |
1,265,253 |
| AKKARAJU SRINIVAS | Director |
Dec 03 '25 |
Buy |
7.75 |
100,000 |
775,000 |
1,012,849 |
| AKKARAJU SRINIVAS | Director |
Dec 02 '25 |
Buy |
7.55 |
96,000 |
724,800 |
912,849 |
| AKKARAJU SRINIVAS | Director |
Dec 04 '25 |
Buy |
8.18 |
66,027 |
540,101 |
1,078,876 |
| AKKARAJU SRINIVAS | Director |
Dec 01 '25 |
Buy |
7.46 |
86,350 |
644,171 |
816,849 |
| AKKARAJU SRINIVAS | Director |
Nov 26 '25 |
Buy |
7.64 |
48,537 |
370,823 |
691,797 |
| AKKARAJU SRINIVAS | Director |
Nov 28 '25 |
Buy |
7.64 |
38,702 |
295,683 |
730,499 |
2.97%
자본화:
|
볼륨(24시간):